Results 1 to 10 of about 172,155 (289)

P13

open access: yesEJC Supplements, 2015
The tumor microenvironment plays an important role in the progression of cancer and may be regulated by proteolysis, including the proteasomes. The proteasomes modify the biologically important molecules involved in the pathogenesis and progression of a ...
E. Shashova   +5 more
doaj   +2 more sources

Discovery of a 0.42-s pulsar in the ultraluminous X-ray source NGC 7793 P13

open access: yesMonthly Notices of the Royal Astronomical Society: Letters, 2017
NGC 7793 P13 is a variable (luminosity range ~100) ultraluminous X-ray source (ULX) proposed to host a stellar-mass black hole of less than 15 M$_{\odot}$ in a binary system with orbital period of 64 d and a 18-23 M$_{\odot}$ B9Ia companion.
G L Israel   +2 more
exaly   +3 more sources

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

open access: yesTherapeutic Advances in Gastroenterology, 2017
Background: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to decrease health-related costs and enhance access to biological therapies.
Joana V Afonso   +2 more
exaly   +2 more sources

Constraints in credit accessibility from primary agricultural cooperative societies in Haryana state, India

open access: yesStudia Ekonomiczne i Regionalne, 2023
The objective of the study was to identify the constraints in credit accessibility from Primary Agricultural Cooperative Societies in Haryana State, India.
Singh Suninder, Singh Abhey, Lal Choote
doaj   +1 more source

Constraints in the Functioning of Primary Agricultural Cooperative Societies in Haryana State, India

open access: yesStudia Ekonomiczne i Regionalne, 2022
Subject and purpose of work: T he s tudy a ims t o identify t he constraints in t he f unctioning of PACS in Haryana, India.
Singh Suninder, Singh Abhey, Lal Choote
doaj   +1 more source

Functional properties and sequence variation of HTLV-1 p13

open access: yesRetrovirology, 2020
Human T cell leukemia virus type-1 (HTLV-1) was the first retrovirus found to cause cancer in humans, but the mechanisms that drive the development of leukemia and other diseases associated with HTLV-1 infection remain to be fully understood. This review
Maria Omsland   +9 more
doaj   +1 more source

Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials

open access: yesArthritis Research & Therapy, 2021
Background A subcutaneous (SC) formulation of infliximab biosimilar CT-P13 is approved in Europe for the treatment of adult patients with rheumatoid arthritis (RA). It may offer improved efficacy versus intravenous (IV) infliximab formulations. Methods A
Bernard Combe   +12 more
doaj   +1 more source

Lytic Phages against ST11 K47 Carbapenem-Resistant Klebsiella pneumoniae and the Corresponding Phage Resistance Mechanisms

open access: yesmSphere, 2022
We isolated and characterized a novel phage from hospital sewage, P13, able to lyse ST11 K47 carbapenem-resistant Klebsiella pneumoniae (CRKP), a major CRKP lineage.
Qingqing Fang, Zhiyong Zong
doaj   +1 more source

Orf-I and Orf-II-Encoded Proteins in HTLV-1 Infection and Persistence

open access: yesViruses, 2011
The 3' end of the human T-cell leukemia/lymphoma virus type-1 (HTLV-1) genome contains four overlapping open reading frames (ORF) that encode regulatory proteins. Here, we review current knowledge of HTLV-1 orf-I and orf-II protein products.
Genoveffa Franchini   +6 more
doaj   +1 more source

A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease

open access: yesTherapeutic Advances in Drug Safety, 2022
Inflammatory bowel diseases (IBDs) are chronic immune disorders of unclear etiology. Tumor necrosis factor (TNF) inhibitors are effective for IBD treatment and are cost-effective because they reduce hospital admissions and are associated with fewer ...
Shin Kashima   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy